U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365423) titled 'Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)' on Jan. 16.
Brief Summary: TerbinaPro is a phase II drug-repurposing study evaluating oral Terbinafine in patients with biochemical recurrence of prostate cancer after prior local treatment with curative intent. When local salvage strategies have been exhausted, recurrence usually reflects micro-metastatic disease without clearly visible metastases on imaging. Standard therapy with androgen deprivation or androgen-receptor pathway inhibitors can effectively control disease but is associated with substantial side effects and negative impact on quality of life. Terb...